BPA Don't know when does the formulation patent run out, I think they are using Antares Pharma's formolation. But since LibiGel is bioidentical testosterone, I don't see what will stop physicians from prescribing generic versions of similar compounds to treat FSD. So far, as reported by BDY, Elestrin (BPA's first product), is not selling very well and Libigel will face the same sort of generic challengers IMO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.